Loss of SLCO1B3 drives taxane resistance in prostate cancer

BACKGROUND: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castration-resistant prostate cancer (mCRPC). However, resistance to taxanes is common. Our objective was to investigate mechanisms of taxane resistance in prostate cancer. METHODS: Two docetaxel-resistant p...

Descripción completa

Detalles Bibliográficos
Autores principales: de Morrée, Ellen S, Böttcher, René, van Soest, Robert J, Aghai, Ashraf, de Ridder, Corrina M, Gibson, Alice A, Mathijssen, Ron HJ, Burger, Herman, Wiemer, Erik AC, Sparreboom, Alex, de Wit, Ronald, van Weerden, Wytske M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023781/
https://www.ncbi.nlm.nih.gov/pubmed/27537383
http://dx.doi.org/10.1038/bjc.2016.251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023781/
https://www.ncbi.nlm.nih.gov/pubmed/27537383
http://dx.doi.org/10.1038/bjc.2016.251

Ejemplares similares